Fig 1: PBX3 is a direct target of miR-320b. (A) Constructed luciferase reporter plasmids containing the predicted WT or MUT miR-320b binding sites on PBX3. (B) A luciferase reporter assay was performed to measure the luciferase activity in AML cells after co-transfection of miRNA mimics and PBX3 WT or MUT. (C) AML cells were transfected with miR-NC mimics or miR-320b mimics and the protein levels of PBX3 measured by western blotting. (D) AML cells were transfected with miR-NC mimics, si-LINC00460 or pcDNA-LINC00460 and the protein levels of PBX3 measured by western blotting. (E) AML cells were transfected with pcDNA3.1 or pcDNA.PBX3 and the protein expression levels of PBX3 measured via western blotting. (F) AML cells were transfected as indicated, and cell viability was measured using the MTT assay. (G) AML cells were transfected as indicated, and the cell cycle distribution was detected. (H) AML cells were transfected as indicated, and cell apoptosis was examined. All experiments were conducted =3 times. Data are presented as the mean ± SD. **P<0.01; ***P<0.001. NC, negative control; miR, microRNA; AML, acute myeloid leukemia; LINC00460, long non-coding RNA 00460; OD, optical density; siRNA, small interfering RNA; PBX3, PBX homeobox 3; WT, wild-type; MUT, mutant.
Supplier Page from Abcam for Anti-Pbx3 antibody